Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun;71(6):e30952.
doi: 10.1002/pbc.30952. Epub 2024 Apr 2.

A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS)

Euan Ballantyne  1 , Connor Evans  2 , Lucy Shepherd  2 , Helen Fulbright  2 , Sara Wakeling  3 , Bob Phillips  2   4 , Jessica E Morgan  2   4
Affiliations
Free article

A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS)

Euan Ballantyne et al. Pediatr Blood Cancer. 2024 Jun.
Free article

Abstract

Approximately one third of children with rhabdomyosarcoma relapse or have refractory disease. Treatment approaches include a combination of systemic therapies and local therapies, directed at tumour site(s). This review was conducted to evaluate the effectiveness and safety of the combination of surgery and brachytherapy as local therapy for treating children and young people with relapsed/refractory rhabdomyosarcoma. This review identified studies based on a previous systematic review looking at the treatments for children and young people under 18 years old with relapsed/refractory rhabdomyosarcoma. Studies conducted after 2000 were included. Survival outcomes, relapse rates, adverse events and functional outcomes were extracted. From 16,965 records identified in the baseline systematic review, 205 included the words 'AMORE' or 'brachytherapy', and were screened for eligibility in this substudy. Thirteen studies met the inclusion criteria for Local-REFoRMS, including over 55 relapsed and refractory rhabdomyosarcoma patients. Most studies were retrospective cohort studies conducted within Europe. Most patients had embryonal disease within the head and neck or bladder/prostate regions, and received local therapy for first relapse. Approximately one quarter of patients relapsed following surgery and brachytherapy, with local relapses occurring more than metastatic relapse. Adverse events and functional outcomes were infrequently reported, but related to the site of surgery and brachytherapy. Study quality was limited by inconsistent reporting and potential selection bias. Outcomes following surgery and brachytherapy for a selected group of relapsed and refractory rhabdomyosarcoma show reasonable benefits, but reporting was often unclear and based on small sample sizes.

Keywords: brachytherapy; childhood cancer; refractory; relapse; rhabdomyosarcoma; surgery.

PubMed Disclaimer

References

REFERENCES

    1. Ferrari A, Dileo P, Casanova M, et al. Rhabdomyosarcoma in adults. Cancer. 2003;98(3):571‐580.
    1. Chen C, Dorado GH, Scheer M, Henssen AG. Current and future treatment strategies for rhabdomyosarcoma. Front Oncol. 2019;9:1458‐1458.
    1. Yang L, Takimoto T, Fujimoto J. Prognostic model for predicting overall survival in children and adolescents with rhabdomyosarcoma. BMC Cancer. 2014;14:654‐654.
    1. American Cancer Society. Survival rates for rhabdomyosarcoma by risk group. American Cancer Society. Accessed October 23, 2023. https://www.cancer.org/cancer/types/rhabdomyosarcoma/detection‐diagnosis...
    1. Heske CM, Mascarenhas L. Relapsed rhabdomyosarcoma. J Clin Med. 2021;10(4):804.

Publication types